These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26683913)

  • 21. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
    Rowe JM; Andersen JW; Mazza JJ; Bennett JM; Paietta E; Hayes FA; Oette D; Cassileth PA; Stadtmauer EA; Wiernik PH
    Blood; 1995 Jul; 86(2):457-62. PubMed ID: 7605984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants.
    Ahmad A; Laborada G; Bussel J; Nesin M
    Pediatr Infect Dis J; 2002 Nov; 21(11):1061-5. PubMed ID: 12442030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
    Lehrnbecher T
    Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review.
    Bohlius J; Reiser M; Schwarzer G; Engert A
    Br J Haematol; 2003 Aug; 122(3):413-23. PubMed ID: 12877668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection against gram-negative bacteremia in neutropenic mice with recombinant granulocyte-macrophage colony-stimulating factor.
    Bermudez LE; Martinelli JC; Gascon R; Wu M; Young LS
    Cytokine; 1990 Jul; 2(4):287-93. PubMed ID: 1966550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
    Schefold JC; Zeden JP; Pschowski R; Hammoud B; Fotopoulou C; Hasper D; Fusch G; Von Haehling S; Volk HD; Meisel C; Schütt C; Reinke P
    Scand J Infect Dis; 2010 Mar; 42(3):164-71. PubMed ID: 19958238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
    Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
    Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High levels of circulating GM-CSF
    Huang H; Wang S; Jiang T; Fan R; Zhang Z; Mu J; Li K; Wang Y; Jin L; Lin F; Xia J; Sun L; Xu B; Ji C; Chen J; Chang J; Tu B; Song B; Zhang C; Wang FS; Xu R
    Cell Mol Immunol; 2019 Jun; 16(6):602-610. PubMed ID: 30327490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compartmentalization of the inflammatory response in sepsis and SIRS.
    Cavaillon JM; Annane D
    J Endotoxin Res; 2006; 12(3):151-70. PubMed ID: 16719987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial.
    Orozco H; Arch J; Medina-Franco H; Pantoja JP; González QH; Vilatoba M; Hinojosa C; Vargas-Vorackova F; Sifuentes-Osornio J
    Arch Surg; 2006 Feb; 141(2):150-3; discussion 154. PubMed ID: 16490891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?
    Perry SE; Mostafa SM; Wenstone R; Shenkin A; McLaughlin PJ
    Intensive Care Med; 2003 Aug; 29(8):1245-52. PubMed ID: 12774155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hematopoietic growth factors in prevention and therapy of infectious complications in premature and newborn infants].
    Lehrnbecher T
    Z Geburtshilfe Neonatol; 2001; 205(5):167-73. PubMed ID: 11727663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis.
    Flohé S; Börgermann J; Domínguez FE; Majetschak M; Lim L; Kreuzfelder E; Obertacke U; Nast-Kolb D; Schade FU
    Shock; 1999 Jul; 12(1):17-24. PubMed ID: 10468047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte-macrophage-colony-stimulating factor-dependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice.
    Spight D; Trapnell B; Zhao B; Berclaz P; Shanley TP
    Shock; 2008 Oct; 30(4):434-42. PubMed ID: 18277945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burn injury and pulmonary sepsis: development of a clinically relevant model.
    Davis KA; Santaniello JM; He LK; Muthu K; Sen S; Jones SB; Gamelli RL; Shankar R
    J Trauma; 2004 Feb; 56(2):272-8. PubMed ID: 14960967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biology and clinical applications of GM-CSF].
    Robak T
    Acta Haematol Pol; 1994; 25(2):99-109. PubMed ID: 8067193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Two-Biomarker Model Predicts Mortality in the Critically Ill with Sepsis.
    Mikacenic C; Price BL; Harju-Baker S; O'Mahony DS; Robinson-Cohen C; Radella F; Hahn WO; Katz R; Christiani DC; Himmelfarb J; Liles WC; Wurfel MM
    Am J Respir Crit Care Med; 2017 Oct; 196(8):1004-1011. PubMed ID: 28418697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.